CDC has announced a Clinician Outreach and Communication Activity (COCA) Call on June 16 to present on medications that are currently available that can reduce chances of severe illness and death from COVID-19 infection. With the current increases in case numbers in Kentucky with the Omicron BA.2 variant and the possibility of other variants arising, we encourage all clinicians who may diagnose and treat COVID-19 patients to attend this webinar to familiarize themselves with the available therapeutics.
Date: Thursday, June 16, 2022
Time: 2:00 PM – 3:00 PM ET
A few minutes before the webinar starts, please click on the Zoom link below to join:
Passcode: 308026
Or Telephone:
US: +1 669 254 5252 or
+1 646 828 7666 or
+1 551 285 1373 or
+1 669 216 1590
Or One-tap mobile:
US: +16692545252,,1603960029#,,,,*308026# or +16468287666,,1603960029#,,,,*308026#
Webinar ID: 160 396 0029
International numbers available: https://www.zoomgov.com/u/ab2qcyEiu7
If you are unable to attend the live COCA Call, the recording will be available for viewing on the COCA Call webpage a few hours after the live event ends.
The slide set will be available on the day of the call on the COCA Call webpage under Call Materials.
Free Continuing Education (CE) will be offered for this COCA Call.
Here is a synopsis of the session:
Medications are available that can reduce chances of severe illness and death from COVID-19 infection. Oral antivirals are available that can reduce chances of severe illness and death from COVID-19 infection. The Food & Drug Administration issued emergency use authorizations for certain antiviral medications and monoclonal antibodies to treat mild to moderate COVID-19 in people who are more likely to get sick. The National Institutes of Health also provides COVID-19 treatment guidelines for healthcare providers for treating COVID-19 at home or in an outpatient setting. During this COCA Call, subject matter experts will present an overview of COVID-19 therapeutic options, including indications, efficacy, and distribution.
Please click here for more detailed information.
